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Background
The etoricoxib can be used as a therapeutical alternative
to patients with hypersensitivity to non-steroidal anti-
inflammatory drugs (NSAIDs). The aim of this study
was to evaluate the use of etoricoxib in daily life of
patients with negative oral drug provocation tests (DPT).
Methods
Patients with hypersensitivity to NSAIDs that performed
a DPT with etoricoxibe between january/2013 and june/
2014 were contacted by phone and asked about poster-
ior etoricoxib drug usage and the occurrence of reac-
tions. Those who had not used again were asked the
reasons for not using.
Results
Forty-one patients were tested, all with negative results.
Thirty seven of them (90%) were contacted and
28 (76%) remembered the tested drug’s name. Twelve of
them (32%) had used the drug again without any reac-
tion. Twenty five patients were not re-exposed: 18 did
not need, 4 were afraid of a new reaction and 3 used
another alternative. Of the 4 patients who were afraid to
use the drug again, 3 of them had presented anaphylaxis
symptoms with other NSAIDs.
Conclusions
Most of the patients exposed to etoricoxib DPT haven’t
been exposed again to the drug. Of those who were
afraid to use the drug again, most had a severe reaction
history to NSAIDs.
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